Catalyst Pharmaceuticals (NASDAQ:CPRX) Given Overweight Rating at Stephens

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report)'s stock had its "overweight" rating reaffirmed by Stephens in a research report issued on Thursday,Benzinga reports. They presently have a $33.00 price objective on the biopharmaceutical company's stock. Stephens' price objective suggests a potential upside of 47.85% from the company's previous close.

Other equities research analysts have also issued reports about the stock. HC Wainwright increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, January 10th. StockNews.com cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, January 11th. Truist Financial lifted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, November 11th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Finally, Robert W. Baird began coverage on Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They set an "outperform" rating and a $28.00 price target on the stock. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $32.50.

Remove Ads

Catalyst Pharmaceuticals Trading Down 2.5 %

Shares of CPRX stock traded down $0.57 on Thursday, reaching $22.32. The company had a trading volume of 1,526,371 shares, compared to its average volume of 1,285,294. The stock has a market cap of $2.66 billion, a PE ratio of 18.92, a PEG ratio of 3.31 and a beta of 0.80. The company has a 50-day moving average of $22.24 and a 200-day moving average of $21.45. Catalyst Pharmaceuticals has a 12 month low of $14.47 and a 12 month high of $24.64.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $29,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $3,733,000. Armis Advisers LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $306,000. Mackenzie Financial Corp increased its position in shares of Catalyst Pharmaceuticals by 132.9% during the 4th quarter. Mackenzie Financial Corp now owns 34,531 shares of the biopharmaceutical company's stock worth $721,000 after purchasing an additional 19,705 shares during the last quarter. Finally, Castlekeep Investment Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $1,775,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.